Follow
Jaeger U*
Jaeger U*
Verified email at meduniwien.ac.at
Title
Cited by
Cited by
Year
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ...
New England Journal of Medicine 380 (1), 45-56, 2019
31822019
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by …
M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ...
The lancet oncology 7 (5), 379-391, 2006
25092006
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ...
The Lancet 376 (9747), 1164-1174, 2010
23772010
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
19122014
bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation
TJ McDonnell, N Deane, FM Platt, G Nunez, U Jaeger, JP McKearn, ...
Cell 57 (1), 79-88, 1989
16041989
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst, R Busch, G Hopfinger, R Pasold, M Hensel, C Steinbrecher, ...
Blood 107 (3), 885-891, 2006
9342006
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ...
New England Journal of Medicine 378 (12), 1107-1120, 2018
9332018
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the …
M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ...
The lancet oncology 12 (11), 1013-1022, 2011
8352011
Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma.
M Seto, U Jaeger, RD Hockett, W Graninger, S Bennett, P Goldman, ...
The EMBO journal 7 (1), 123-131, 1988
6481988
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ...
Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014
6242014
How I treat autoimmune hemolytic anemias in adults
K Lechner, U Jäger
Blood, The Journal of the American Society of Hematology 116 (11), 1831-1838, 2010
4302010
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion …
AV Kurtova, K Balakrishnan, R Chen, W Ding, S Schnabl, MP Quiroga, ...
Blood, The Journal of the American Society of Hematology 114 (20), 4441-4450, 2009
4222009
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ...
American journal of hematology 94 (12), 1353-1363, 2019
4142019
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas
B Streubel, A Chott, D Huber, M Exner, U Jäger, O Wagner, ...
New England Journal of Medicine 351 (3), 250-259, 2004
3852004
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill, QA Hill, B Jilma, ...
Blood reviews 41, 100648, 2020
3832020
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
N Pflug, J Bahlo, TD Shanafelt, BF Eichhorst, MA Bergmann, T Elter, ...
Blood, The Journal of the American Society of Hematology 124 (1), 49-62, 2014
3592014
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic …
S Stilgenbauer, T Zenz, D Winkler, A Buehler, RF Schlenk, S Groner, ...
Journal of Clinical Oncology 27 (24), 3994-4001, 2009
3492009
Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free …
M Hallek, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, ...
Blood 112 (11), 325, 2008
3422008
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ...
Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018
3402018
Consensus statement on the use of rituximab in patients with rheumatoid arthritis
JS Smolen, EC Keystone, P Emery, FC Breedveld, N Betteridge, ...
Annals of the rheumatic diseases 66 (2), 143-150, 2007
3312007
The system can't perform the operation now. Try again later.
Articles 1–20